- Home
- AIXC vs GNPX Comparison
AIXC vs GNPX Comparison
Compare AIXC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIXC
- GNPX
- Stock Information
- Founded
- AIXC 1996
- GNPX 2009
- Country
- AIXC United States
- GNPX United States
- Employees
- AIXC N/A
- GNPX N/A
- Industry
- AIXC Biotechnology: Pharmaceutical Preparations
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- AIXC Health Care
- GNPX Health Care
- Exchange
- AIXC Nasdaq
- GNPX Nasdaq
- Market Cap
- AIXC 13.1M
- GNPX 10.8M
- IPO Year
- AIXC N/A
- GNPX 2018
- Fundamental
- Price
- AIXC $2.55
- GNPX $2.82
- Analyst Decision
- AIXC
- GNPX
- Analyst Count
- AIXC 0
- GNPX 0
- Target Price
- AIXC N/A
- GNPX N/A
- AVG Volume (30 Days)
- AIXC 311.6K
- GNPX 521.3K
- Earning Date
- AIXC 11-21-2025
- GNPX 11-14-2025
- Dividend Yield
- AIXC N/A
- GNPX N/A
- EPS Growth
- AIXC N/A
- GNPX N/A
- EPS
- AIXC N/A
- GNPX N/A
- Revenue
- AIXC N/A
- GNPX N/A
- Revenue This Year
- AIXC N/A
- GNPX N/A
- Revenue Next Year
- AIXC N/A
- GNPX N/A
- P/E Ratio
- AIXC N/A
- GNPX N/A
- Revenue Growth
- AIXC N/A
- GNPX N/A
- 52 Week Low
- AIXC $1.61
- GNPX $2.77
- 52 Week High
- AIXC $8.81
- GNPX $63.00
- Technical
- Relative Strength Index (RSI)
- AIXC N/A
- GNPX 41.66
- Support Level
- AIXC N/A
- GNPX $7.71
- Resistance Level
- AIXC N/A
- GNPX $5.00
- Average True Range (ATR)
- AIXC 0.00
- GNPX 0.72
- MACD
- AIXC 0.00
- GNPX -0.38
- Stochastic Oscillator
- AIXC 0.00
- GNPX 1.70
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.